The MA39 TAILOR RT will focus on regional radiation therapy and will assign HR+/HER2- low-risk (defined by an OncotypeDX © Recurrence Score < 18) breast cancer patients with up to three positive axillary nodes to regional radiation therapy or observation (NCT03488693) [73]. This evidence concerns the gene ERBB2 and breast carcinoma.